Pharmacology, Toxicology and Pharmaceutical Science
Fludarabine
100%
Cytarabine
88%
Chronic Lymphatic Leukemia
80%
Leukemia
53%
Vidarabine
36%
Acute Myeloid Leukemia
35%
Gemcitabine
33%
Pharmacokinetic
31%
Remission
27%
Clofarabine
24%
Nucleoside Analog
23%
Adenosine Triphosphate
22%
Acute Leukemia
22%
Cytidine Triphosphate
21%
Cytotoxicity
19%
Nucleoside
16%
Diseases
14%
Neoplasm
14%
Pharmacodynamics
14%
Chemotherapy
12%
Combination Therapy
12%
Hematologic Malignancy
11%
Clinical Trial
11%
Cyclophosphamide
10%
Nelarabine
9%
Cladribine
9%
Chronic Myeloid Leukemia
9%
Rituximab
9%
Deoxyribonucleotide
8%
Sapacitabine
8%
Deoxycytidine
8%
Fludarabine Phosphate
8%
Prodrug
8%
Infection
7%
Solid Malignant Neoplasm
7%
Oxaliplatin
7%
Elimination
7%
deoxyribonucleic acid nucleotidyl transferase
7%
Bone Marrow Suppression
6%
Guanine
6%
Deoxycytidine Kinase
6%
Phase I Trials
6%
Acute Lymphoblastic Leukemia
5%
7 Hydroxystaurosporine
5%
Active Metabolite
5%
Mitoxantrone
5%
Maximum Tolerated Dose
5%
Ibrutinib
5%
Cisplatin
5%
Chinese hamster
5%
Keyphrases
Fludarabine
50%
Chronic Lymphocytic Leukemia
46%
Triphosphate
29%
Nucleoside Analogues
23%
Metabolism
22%
5-bisphosphate
21%
Ara-C
21%
Gemcitabine
19%
Relapsed or Refractory Acute Myeloid Leukemia
18%
Acute Myeloid Leukemia
18%
Clofarabine
14%
Cytarabine
14%
Pharmacokinetics
14%
Relapsed or Refractory
13%
2-fluoroadenine
13%
Ara-CTP
12%
DNA Synthesis
12%
Complete Remission
12%
Hematological Malignancies
12%
CNDAC
12%
Arabinofuranosylcytosine
12%
Leukemia Cells
12%
Chronic Lymphocytic Leukemia Cells
11%
Cytotoxicity
11%
Chronic Myeloid Leukemia
10%
Leukemia
10%
Nucleosides
9%
Human Leukemia Cells
9%
Mechanism of Action
9%
Cell Death
9%
Cellular Pharmacology
9%
DNA Damage
9%
Leukemic Cells
8%
Induced Apoptosis
8%
Phase I Study
8%
Cyano
8%
Apoptosis
8%
Sapacitabine
7%
Monophosphate
7%
DNA Repair
7%
High-dose Cytosine Arabinoside
7%
Pharmacologic
7%
Phase II Study
7%
Cyclophosphamide
7%
DNA Polymerase
7%
Cellular Pharmacokinetics
6%
Incubation
6%
Combination Therapy
6%
DNA Strands
6%
Continuous Infusion
6%
Biochemistry, Genetics and Molecular Biology
Fludarabine
38%
Gemcitabine
32%
Programmed Cell Death
26%
Nucleoside Analog
25%
Cytarabine
19%
DNA Synthesis
14%
Vidarabine
14%
Cytotoxicity
12%
Metabolic Pathway
12%
DNA Repair
12%
Pharmacokinetic
11%
DNA Strand
10%
Lymphocyte
10%
DNA Damage
10%
P53
9%
Base Excision Repair
9%
Myeloid
9%
S Phase
9%
Cell Death
8%
deoxyribonucleic acid nucleotidyl transferase
8%
Metabolite
7%
Nucleoside
7%
Deoxycytidine
7%
Nucleotide Excision Repair
7%
Deoxyribonucleotide
7%
Cytidine Triphosphate
7%
Homologous Recombination
6%
DNA Fragmentation
6%
Phosphotransferase
6%
Kinase
6%
Pyrophosphate
6%
Ataxia Telangiectasia Mutated
6%
Anticancer
5%
Pharmacodynamics
5%
Cisplatin
5%
MicroRNA
5%
Protein Kinase
5%
Transcription
5%
Adenosine Triphosphate
5%
Clinical Trial
5%
G2 Phase Cell Cycle Checkpoint
5%